BioTuesdays: Oramed sees value creating events through 2016
Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about Oramed’s progress and future advances. “Our ORMD-0801 drug candidate has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications” http://www.biotuesdays.com/features/2015/12/1/oramed-sees-value-creating-events-through-2016
Seeking Alpha: $50 Million Plus Royalties Deal Indicates Bright Future For Oramed’s Oral Insulin
seekingalpha.com/article/3723676-50-million-plus-royalties-deal-indicates-bright-future-for-orameds-oral-insulin?app=1&auth_param=k8111%3A1b5r8j9%3A005181aa590ef2f22df1979bdbb995c2&uprof=78
In-Pharma: Oramed Inks China Licensing Deal for Oral Insulin Candidate
www.in-pharmatechnologist.com/Drug-Delivery/Oramed-inks-China-licensing-deal-for-oral-insulin-candidate
Times of Israel: Oramed inks huge $50m deal with Chinese pharma firm
www.timesofisrael.com/oramed-inks-huge-50m-deal-with-chinese-pharma-firm/?utm_source=dlvr.it&utm_medium=twitter
